500 related articles for article (PubMed ID: 30573629)
1. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Ruscetti M; Leibold J; Bott MJ; Fennell M; Kulick A; Salgado NR; Chen CC; Ho YJ; Sanchez-Rivera FJ; Feucht J; Baslan T; Tian S; Chen HA; Romesser PB; Poirier JT; Rudin CM; de Stanchina E; Manchado E; Sherr CJ; Lowe SW
Science; 2018 Dec; 362(6421):1416-1422. PubMed ID: 30573629
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle inhibitors make progress.
Brower V
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25006194
[No Abstract] [Full Text] [Related]
3. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
4. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Inao T; Kotani H; Iida Y; Kartika ID; Okimoto T; Tanino R; Shiba E; Harada M
Cancer Sci; 2019 Sep; 110(9):2690-2699. PubMed ID: 31250942
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
6. Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
Son KH; Kim MY; Shin JY; Kim JO; Kang JH
Anticancer Res; 2021 Oct; 41(10):4807-4820. PubMed ID: 34593430
[TBL] [Abstract][Full Text] [Related]
7. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
9. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
10. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
11. A combinatorial strategy for treating KRAS-mutant lung cancer.
Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
13. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
14. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.
Maust JD; Frankowski-McGregor CL; Bankhead A; Simeone DM; Sebolt-Leopold JS
Mol Cancer Ther; 2018 Dec; 17(12):2495-2506. PubMed ID: 30254182
[TBL] [Abstract][Full Text] [Related]
16. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
17. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
Sumi NJ; Kuenzi BM; Knezevic CE; Remsing Rix LL; Rix U
ACS Chem Biol; 2015 Dec; 10(12):2680-6. PubMed ID: 26390342
[TBL] [Abstract][Full Text] [Related]
18. [CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
Gonçalves A
Bull Cancer; 2018 Jun; 105(6):545-546. PubMed ID: 29729807
[No Abstract] [Full Text] [Related]
19. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
20. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
